Dainippon Sumitomo Pharma Kicks Off Orphan Aid Program
This article was originally published in PharmAsia News
Executive Summary
China's Children and Teenagers' Fund and Dainippon Sumitomo Pharma Suzhou recently started a project for helping school-age orphans. The program aims to publicize the living and educational conditions of ethnic orphans in remote and poverty-stricken areas to encourage more people to participate in the care of such children. As a major proponent of the activity, Dainippon Sumitomo donated special funds to a school in Yunnan to help 50 orphans complete junior high school. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.